智通财经网·2025-09-18 01:55Core Insights - Rongchang Biopharma (09995) shares rose over 8%, reaching HKD 115 with a trading volume of HKD 222 million [1] Group 1: Clinical Development - On September 18, Rongchang Biopharma announced that its self-developed innovative drug, RC18 (brand name: Tai'ai®), targeting both BLyS and APRIL, has successfully completed a 48-week open-label extension study for the treatment of generalized Myasthenia Gravis (gMG) [1] - The long-term efficacy data from this study has been selected for an oral presentation at the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, scheduled for October 29 to November 1 in San Francisco, California [1] Group 2: Strategic Partnerships - Rongchang Biopharma disclosed during its earnings briefing that in August 2021, it entered into a global exclusive licensing agreement with Seattle Genetics (now acquired by Pfizer Inc.) for the global development and commercialization rights of RC48 outside of its region (excluding Japan and Singapore) [1] - Currently, the clinical trials for RC48 are being advanced as planned by Pfizer in overseas markets [1]